Free Trial
NASDAQ:MNPR

Monopar Therapeutics (MNPR) Stock Price, News & Analysis

Monopar Therapeutics logo
$35.16 +1.60 (+4.77%)
Closing price 04:00 PM Eastern
Extended Trading
$34.07 -1.09 (-3.09%)
As of 05:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Monopar Therapeutics Stock (NASDAQ:MNPR)

Key Stats

Today's Range
$33.54
$36.11
50-Day Range
$30.01
$44.96
52-Week Range
$1.72
$54.30
Volume
60,928 shs
Average Volume
359,313 shs
Market Capitalization
$215.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$56.50
Consensus Rating
Moderate Buy

Company Overview

Monopar Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

MNPR MarketRank™: 

Monopar Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 425th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Monopar Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Monopar Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Monopar Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Monopar Therapeutics are expected to decrease in the coming year, from ($1.65) to ($2.51) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Monopar Therapeutics is -10.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Monopar Therapeutics is -10.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Monopar Therapeutics has a P/B Ratio of 3.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Monopar Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.63% of the float of Monopar Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Monopar Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Monopar Therapeutics has recently decreased by 25.88%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Monopar Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Monopar Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.63% of the float of Monopar Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Monopar Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Monopar Therapeutics has recently decreased by 25.88%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Monopar Therapeutics has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Monopar Therapeutics this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added Monopar Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Monopar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,166,690.00 in company stock.

  • Percentage Held by Insiders

    20.50% of the stock of Monopar Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 1.83% of the stock of Monopar Therapeutics is held by institutions.

  • Read more about Monopar Therapeutics' insider trading history.
Receive MNPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MNPR Stock News Headlines

Chardan Capital Comments on MNPR FY2025 Earnings
Banks aren’t ready for this altcoin—are you?
In crypto, timing is everything. By the time the masses catch wind of this, the biggest gains could be ancient history. Are you ready to potentially change your financial future forever?
See More Headlines

MNPR Stock Analysis - Frequently Asked Questions

Monopar Therapeutics' stock was trading at $22.00 on January 1st, 2025. Since then, MNPR stock has increased by 59.8% and is now trading at $35.16.
View the best growth stocks for 2025 here
.

Monopar Therapeutics Inc. (NASDAQ:MNPR) posted its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.27.

Shares of Monopar Therapeutics reverse split on Tuesday, August 13th 2024.The 1-5 reverse split was announced on Friday, August 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Monopar Therapeutics subsidiaries include these companies: Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL.

Monopar Therapeutics (MNPR) raised $9 million in an IPO on Thursday, December 19th 2019. The company issued 1,100,000 shares at $8.00 per share. JonesTrading served as the underwriter for the IPO and Arcadia Securities was co-manager.

Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Monopar Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Avino Silver & Gold Mines (ASM), GlycoMimetics (GLYC), Tonix Pharmaceuticals (TNXP) and Viking Therapeutics (VKTX).

Company Calendar

Last Earnings
5/13/2025
Today
7/02/2025
Next Earnings (Estimated)
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MNPR
Fax
N/A
Employees
10
Year Founded
2014

Price Target and Rating

Average Stock Price Target
$56.50
High Stock Price Target
$76.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+60.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$15.59 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$9.02 per share
Price / Book
3.90

Miscellaneous

Free Float
4,861,000
Market Cap
$215.00 million
Optionable
Not Optionable
Beta
1.01

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:MNPR) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners